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Objectives The study sought to measure the prevalence, disease burden, and determinants of mortality in geriatric adults
with congenital heart disease (ACHD).
Background The population of ACHD is increasing and aging. The geriatric ACHD population has yet to be characterized.
Methods Population-based cohort study using the Quebec Congenital Heart Disease Database of all patients with congeni-
tal heart disease coming into contact with the Quebec healthcare system between 1983 and 2005. Subjects
with specific diagnoses of congenital heart disease and age 65 years at time of entry into the cohort were fol-
lowed for up to 15 years. The primary outcome was all-cause mortality.
Results The geriatric ACHD cohort consisted of 3,239 patients. From 1990 to 2005, the prevalence of ACHD in older
adults remained constant from 3.8 to 3.7 per 1,000 indexed to the general population (prevalence odds ratio:
0.98; 95% confidence interval [CI]: 0.93 to 1.03). The age-stratified population prevalence of ACHD was similar
in older and younger adults. The most common types of congenital heart disease lesions in older adults were
shunt lesions (60%), followed by valvular lesions (37%) and severe congenital heart lesions (3%). Type of ACHD
and ACHD-related complications had a minor impact on mortality, which was predominantly driven by acquired
comorbid conditions. The most powerful predictors of mortality in the Cox proportional hazards model were: de-
mentia (hazard ratio [HR]: 3.24; 95% CI: 1.53 to 6.85), gastrointestinal bleed (HR: 2.79; 95% CI: 1.66 to 4.69),
and chronic kidney disease (HR: 2.50; 95% CI: 1.72 to 3.65).
Conclusions The prevalence of geriatric ACHD is substantial, although severe lesions remain uncommon. ACHD patients that
live long enough acquire general medical comorbidities, which are the pre-eminent determinants of their
mortality. (J Am Coll Cardiol 2011;58:1509–15) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.041The prevalence of adults with congenital heart disease
(ACHD) is rising in the general population (1), and
healthcare utilization rates are high compared with non-
ACHD adults (2). Not surprisingly, the number of older
adults above age 65 years with ACHD is also rising, with
admission rates increasing by 30% for this group of
patients over the past 10 years (3). Furthermore, mortal-
ity rates in congenital heart disease have shifted away
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in age at death (4).
In contrast to the younger ACHD population that has
attracted research interest over the last 2 decades, the
geriatric ACHD population has yet to be characterized.
Extrapolation of studies on younger patients is not appro-
priate. First, older adults with ACHD acquire comorbid
conditions that may play a significant role in their health
status. Second, geriatric ACHD patients may have inher-
ently superior resiliency, milder disease, or balanced physi-
ology in contrast to those not surviving to an advanced age
(5). Therefore, older adults with ACHD represent a distinct
population for which focused studies are needed. Global
disease burden is driving costs and outcomes in the United
States and Canada, thus becoming relevant to policymakers
and ACHD specialists. This is likely to have important
implications in planning for future allocation of resources in
this growing population.
Our objective was to analyze trends in numbers of older
adults with ACHD over the past 15 years and to identify
the determinants of mortality. In particular, the impact on
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ity, ACHD-related complica-
tions, and acquired comorbid
conditions was measured in a
large population-based cohort of
older adults with ACHD.
Methods
Study design and data sources.
A population-based cohort of
older adults with ACHD was extracted from the Quebec
Congenital Heart Disease Database (1,4). The Quebec
Congenital Heart Disease Database consists of all ACHD
patients coming into contact with the healthcare system in
Quebec between 1983 and 2005. The healthcare system in
Quebec is a single-payer system offering comprehensive and
universal access to healthcare services. Utilization of these
healthcare services is tied to a unique patient identifier
number that was used to cross-link the physician’s services
and claims database (Régie de l’Assurance Maladie du
Québec), the hospital discharge database (Med-Echo), and
the Quebec death registry. To protect patient confidential-
ity, data were transmitted with encrypted identifiers. Per-
mission was obtained from the McGill University Health
Center ethics board and government agencies responsible
for privacy of access to information.
Study population. Inclusion criteria were age 65 years at
any point during the time period of 1990 to 2005, and
confirmed diagnosis of ACHD. The diagnosis of ACHD
was ascertained based on a hierarchical diagnostic algorithm
that has been validated in prior studies (1,4) and adapted to
the current study to exclude elderly patients who had an
isolated diagnostic code for ACHD without confirmation
by a cardiovascular specialist or ACHD-related hospitaliza-
tions or surgeries. This algorithm contains 24 International
Classification of Diseases-9th edition (ICD-9), codes for
ACHD diagnosis and surgery, weighted according to the
frequency of the code (multiple vs. isolated) and the physi-
cian making it (cardiovascular specialist vs. other). Uncer-
tain diagnoses were hand-checked and audited by 2 inde-
pendent observers and either excluded, validated, or
reclassified. Patients with nonspecific diagnostic codes for
ACHD were excluded (unspecified anomalies of the heart
[ICD-9 codes 7468–7469], unspecified anomalies of the
aorta [ICD-9 code 7472], unspecified anomalies of the
circulation [ICD-9 code 7479]).
Predictor variables and covariates. ACHD lesions were
grouped into 3 categories: severe lesions (tetralogy of Fallot,
transposition of the great arteries, endocardial cushion
defect, Ebstein anomaly, truncus arteriosus, univentricular
heart, hypoplastic left heart syndrome), shunt lesions (atrial
septal defect, ventricular septal defect, patent ductus arteri-
osus), and congenital regurgitant or stenotic lesions termed
valvular lesions (congenital aortic stenosis, congenital aortic
Abbreviations
and Acronyms
ACHD  adult congenital
heart disease
CI  confidence interval
HR  hazard ratio
ICD-9  International
Classification of Diseases-
9th editionregurgitation, congenital mitral stenosis, congenital mitralregurgitation, congenital tricuspid valve disease, anomalies
of the pulmonary valve, aortic coarctation) (1,4). Severe
lesions reflect lesions with the highest probability of being
associated with cyanosis or requiring surgical intervention in
early life (1,4).
ACHD-related complications and acquired comorbid
conditions were analyzed (Table 1). Diagnostic codes for
comorbid conditions were available from 1983 onward. For
patients entering the cohort in the first year (1990), there
were 7 years of prior records for ascertainment of comorbid
conditions (1983 to 1990). For patients entering the cohort
in later years, there were more prior records, although a
fixed time period of 7 years prior to entry in the cohort was
used in order to allow all patients to have equal ascertain-
ment time. Recognizing that there may be overlap between
what would be considered an ACHD complication or an
acquired comorbid condition (e.g., heart failure), variables
were entered individually and not grouped in the analytical
model.
Outcome and censoring. The primary endpoint was all-
cause mortality. Vital status was determined in the physi-
cian’s services and claims database and the Quebec death
registry. The Quebec civil code (section III, articles 122–128)
mandates that all deaths be ascertained by law and for-
warded to the physician’s services and claims database. In a
study of patients with prior myocardial infarction conducted
in the medical claims database of Quebec, vital status was
determined in 99.75% of subjects (6). Ascertainment of
mortality in the Quebec Congenital Heart Disease Database
has been previously published by our group (4). Patients
were followed for up to 15 years (up to 80 years of age), from
their respective entry into the study cohort until death or
end of follow-up.
Statistical analysis. Baseline characteristics of patients
with severe, shunt, and valvular lesions were compared with
the chi-square test. Prevalence was measured by dividing the
number of patients with a confirmed diagnosis of ACHD in
the provincial ACHD database during the calendar years of
1990, 1995, 2000, and 2005 by the midyear general popu-
lation estimates matched for age group and calendar year
from the provincial census (Statistics Canada [7]). Preva-
lence was measured for the adult age group (age 18 to 64
years) and the elderly age group (age 65 years and above).
The change in prevalence between the first calendar year
(1990) and the last (2005) was compared using the preva-
lence odds ratio with an associated 95% confidence interval.
The effect of predictors and covariates on all-cause mortality
was measured using a Cox proportional hazards model,
where time zero was age 65 years and the time axis was age
(range 65 to 80 years). The proportionality of hazards was
verified graphically by the log-log survival plot. The list of
predictors and covariates were pre-specified and determined
based on a priori knowledge. To account for possible
time-dependent effects of ACHD-related complications
and acquired comorbid conditions, a sensitivity analysis
using a nested case-control model was performed. In such a
hemic
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ates is ascertained within a fixed time period before events
(death or selection as a control) rather than before entry in
the cohort. To account for potential misclassification due to
errors in grouping lesions into 3 exclusive categories, a
sensitivity analysis using 3 individual lesions representative
of each category was performed. These representative indi-
vidual lesions were tetralogy of Fallot (severe), atrial septal
defect (shunt), and congenital aortic stenosis (valvular).
Analyses were performed with the SAS statistical software
package (version 8.02, Cary, North Carolina).
Results
Prevalence of geriatric ACHD. The Quebec Congenital
Heart Disease Database consisted of 71,467 patients, of
which 44,865 were adults during the study period. After
excluding nonelderly patients and those with nonspecific
ACHD diagnoses, the geriatric ACHD cohort consisted of
3,239 older adults age 65 years at any point between 1990
and 2005. The flow diagram depicting the derivation of the
study cohort is shown in Figure 1. The prevalence of
ACHD in the geriatric population was found to be 3.8 per
1,000 in 1990 and 3.7 per 1,000 in 2005, representing a
constant prevalence (prevalence odds ratio: 0.98; 95% con-
Patient Characteristics Grouped By ACHD LesioTable 1 Patient Characteristics Grouped By
All Lesions
(n  3,239)
Sh
(n 
Male 1,440 (44) 76
Atrial fibrillation 681 (21) 43
Ventricular arrhythmia 99 (3) 6
Sick sinus syndrome 145 (4) 8
Heart block 139 (4) 7
Endocarditis 31 (1) 1
Pulmonary hypertension 186 (6) 11
Erythrocytosis 61 (2) 3
Epilepsy 61 (2) 3
Diabetes 527 (16) 31
Dyslipidemia 875 (27) 48
Hypertension 1,534 (47) 91
Coronary artery disease 339 (10) 20
Myocardial infarction 216 (7) 14
Heart failure 667 (21) 39
Stroke/TIA 330 (10) 20
Chronic kidney disease 75 (2) 4
Chronic liver disease 61 (2) 2
COPD 254 (8) 15
Pneumonia 93 (3) 5
Thyroid disease 431 (13) 26
Cancer 542 (17) 31
Deep vein thrombosis 38 (1) 2
Gastrointestinal bleed 33 (1) 1
Depression 212 (7) 11
Dementia 20 (1) 1
Values are n (%).
COPD  chronic obstructive pulmonary disease; TIA  transient iscfidence interval [CI]: 0.93 to 1.03). In comparison, theprevalence of ACHD in the nongeriatric adult population
(age 18 to 64 years) was found to be 3.1 per 1,000 in 1990
and 4.2 per 1,000 in 2005, representing a 37% increase in
odds (prevalence odds ratio: 1.37; 95% CI: 1.34 to 1.40).
Trends in prevalence are shown in Figure 2.
Baseline characteristics of study population. Patient
characteristics grouped by type of ACHD lesion are shown
in Table 1. The most frequent type of ACHD lesion in
older adults was shunts (60%), followed by valvular (37%)
and severe lesions (3%). Severe ACHD lesions were rare,
and mostly consisted of conotruncal abnormalities and
endocardial cushion defects; whereas nonsevere lesions
mostly consisted of atrial septal defects, ventricular septal
defects, congenital aortic stenosis, and congenital mitral
insufficiency. Covariates were generally well balanced be-
tween groups, although patients with severe lesions were
more likely to have atrial fibrillation (p  0.002), heart
block (p  0.001), and pulmonary hypertension (p 
0.006). Patients with valvular lesions were more likely to be
male (p  0.0001) and have had endocarditis in the past (p
 0.006).
Mortality. During a median follow-up of 6.9 years (Q1,
Q3: 3.3, 10.7 years), 630 deaths were observed. The
Kaplan-Meier analysis revealed a projected 15-year survival
eD Lesion Type
)
Severe
(n  82)
Valvular
(n  1,211) p Value
32 (39) 642 (53) 0.0001
26 (32) 222 (18) 0.002
4 (5) 30 (2) 0.24
5 (6) 51 (4) 0.69
10 (12) 55 (5) 0.001
0 (0) 20 (2) 0.006
7 (9) 60 (5) 0.006
1 (1) 23 (2) 0.90
0 (0) 27 (2) 0.28
11 (13) 198 (16) 0.78
27 (33) 368 (30) 0.001
38 (46) 582 (48) 0.82
13 (16) 120 (10) 0.23
9(11) 66 (5) 0.04
22 (27) 253 (21) 0.32
3 (4) 126 (10) 0.14
1 (1) 33 (3) 0.43
2 (2) 30 (2) 0.13
5 (6) 91 (8) 0.69
4 (5) 38 (3) 0.38
13 (16) 149 (12) 0.37
9 (11) 216 (18) 0.19
2 (2) 8 (1) 0.08
1 (1) 13 (1) 0.95
9 (11) 88 (7) 0.08
0 (0) 5 (0.4) 0.35
attack.n TypACH
unts
1,946
6 (39)
3 (22)
5 (3)
9 (5)
4 (4)
1 (1)
5 (6)
7 (2)
4 (2)
8 (16)
0 (25)
4 (47)
6 (11)
1 (7)
2 (20)
1 (10)
1 (2)
9 (1)
8 (8)
1 (3)
9 (14)
7 (16)
8 (1)
9 (1)
5 (6)
5 (1)rate of 56.2%. Survival was similar regardless of ACHD
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66.8% in severe lesions, log-rank p  0.09) (Fig. 3). After
adjusting for potential confounders, ACHD lesion type
remained a nonsignificant predictor of survival. Unadjusted
and adjusted predictors of all-cause mortality are shown in
Table 2.
Nine independent predictors of increased all-cause
mortality were identified, all of which had been classified
Figure 1 Flow Diagram for Derivation of Study Cohort
The geriatric CHD cohort included patients with a confirmed diagnosis of congenital he
Figure 2 Trends in Prevalence of ACHD in Different Age
Groups
In 2005, the prevalence of ACHD was 3.7 per 1,000 in the elderly and 4.2 per
1,000 in nonelderly adults. Using 1990 as a reference, the prevalence
remained constant in the elderly (prevalence odds ratio: 0.98; 95% confidence
interval [CI]: 0.93 to 1.03), whereas it increased in nonelderly adults (preva-
lence odds ratio: 1.37; 95% CI: 1.34 to 1.40).as acquired cardiovascular and general medical condi-
tions. In descending order of magnitude, these were
dementia (hazard ratio [HR]: 3.24; 95% CI: 1.53 to
6.85), gastrointestinal bleed (HR: 2.79; 95% CI: 1.66 to
4.69), chronic kidney disease (HR: 2.50; 95% CI: 1.72 to
3.65), heart failure (HR: 1.98; 95% CI: 1.65 to 2.38),
diabetes mellitus (HR: 1.76; 95% CI: 1.45 to 2.13),
chronic obstructive pulmonary disease (HR: 1.67; 95%
CI: 1.31 to 2.12), cancer (HR: 1.43; 95% CI: 1.17 to
ease (CHD) who were 65 years of age at any point between 1990 and 2005.
Figure 3 Kaplan-Meier Curves for Unadjusted All-Cause
Mortality
The 15-year survival was 56%; 67% for patients with severe lesions, 55% for
patients with shunts, and 58% for patients with valvular lesions (log-rank
p0.09).art dis
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1.83), and male sex (HR: 1.33; 95% CI: 1.13 to 1.55).
Sensitivity analysis. In a sensitivity analysis comparing 3
representative individual ACHD lesions (tetralogy of Fallot,
atrial septal defect, and congenital aortic stenosis), ACHD
lesion type remained a nonsignificant predictor of all-cause
mortality, and the Cox proportional hazards model yielded
similar results. A nested case-control model, performed to
better account for the time-dependency of covariates, also
yielded similar results.
Discussion
To our knowledge, this is the first study to specifically
address the population of older adults with ACHD. We
present data on the prevalence, disease burden, and predic-
tors of mortality in a large population-based geriatric
ACHD cohort. The contemporary prevalence of geriatric
ACHD was found to be 3.7 per 1,000 older adults, which is
slightly lower than that in nongeriatric patients, but high
enough to document that the absolute number of older
adults with ACHD is substantial. ACHD patients survived
long enough to acquire a significant disease burden from
general medical conditions, which were the main determi-
nants of their mortality. Dementia, chronic kidney disease,
and gastrointestinal bleeding were the most powerful pre-
dictors of all-cause mortality over a 15-year period.
The correlates of survival in patients with congenital
heart defects vary with age. In infants and children, lesion
severity and surgical results have been shown to be the
primary determinants of mortality (8,9). In young and
middle-aged adults, ACHD-related complications begin to
play a larger role in determining outcomes; especially
cyanosis, pulmonary hypertension, heart failure, and ar-
rhythmias (10–15). In older adults, our findings suggest
that acquired medical conditions have the greatest impact
on mortality. These acquired medical conditions mirror the
most common causes of death in the general population
(16), with the addition of gastrointestinal bleeding, which is
increasingly recognized as a powerful predictor of mortality
in patients taking antiplatelet and anticoagulant therapies
(17,18) (a substantial proportion of patients in this cohort
had atherosclerotic disease and atrial fibrillation). ACHD
lesion type was not an independent predictor of mortality
after adjusting for confounders. ACHD-related complica-
tions were similarly not independent predictors of mortality
(with the exception of heart failure, which may or may not
be ACHD related).
There are at least 3 reasons for which acquired comorbid
conditions and not ACHD lesion type or complications had
an impact on mortality in older patients. First, the preva-
lence of severe lesions and/or severe complications in older
adults (and consequently, the statistical power in this subset
of patients) was relatively low and remained constant
throughout the study period, in part as a result of the lack of
effective therapeutic options in the 1920s and 1930s, when vmost of this study cohort was born. With the evolution of
congenital cardiac surgery, as well as sensitive diagnostic
testing and greater general life expectancy, many more
patients with severe ACHD (including those with very
complex lesions) are expected to survive to an advanced age.
This phenomenon has been observed in the nongeriatric
adult population wherein the prevalence of adults with
severe ACHD is rising faster than the prevalence of children
with severe ACHD (prevalence odds ratio: 1.85 vs. 1.22) (1).
his should translate into an increasing prevalence of older
dults with severe ACHD, and possibly an increasing propor-
ion of older adults dying from ACHD-related conditions.
Second, the number of older adults with atrial septal defects
nd valvular lesions was high, representing the majority of our
ohort. Prior studies have shown that the most common causes
f death in patients with atrial septal defects are noncardiac
19), whereas in patients with repaired bicuspid aortic valves,
hey tend to be perioperative or related to coronary artery
isease (20). Even in an unselected population of young adults
ith ACHD, one-third of deaths were noncardiac in origin
21). The proportion of deaths attributable to ACHD is much
igher in studies focusing on complex and relatively rare
athophysiologies such as Fontan or Eisenmenger, which may
ot be generalizable to ACHD patients at large. Within the
mall group of patients with severe lesions, the majority
onsisted of tetralogy of Fallot and endocardial cushion defects,
or which there are well-recognized balanced and partial
ariants, respectively. Although higher than nonsevere lesions,
he modest rates of heart failure (27%) and pulmonary hyper-
ension (9%) suggest that many of the older adults with severe
esions in this study had either balanced or minor variants
llowing them to naturally survive to an advanced age, or had
perated lesions with favorable results.
Third, the number of older ACHD patients with docu-
ented cardiovascular disease and risk factors was substantial
7% prevalence of myocardial infarction as compared with an
ge-matched prevalence of 5% in Canada [22]), leading to a
arge burden of atherosclerotic disease. The burden of athero-
clerotic disease in older adults with ACHD is clearly driven by
ge but may also be associated with ACHD. Billet et al. (23)
ound that adults with ACHD were more likely to have
ypertension, diabetes, stroke, and chronic kidney disease (a
oronary artery disease risk equivalent) than age-matched
ontrols without ACHD. Moons et al. (24) found that at least
0% of adults with ACHD had at least 1 coronary artery
isease risk factor, with the rates of hypertension and obesity
eing more common than the general population. The mean
ge in both of these studies was only 26 to 28 years, suggesting
hat ACHD patients may harbor risk factors for many years. It
s, therefore, not surprising that by the time they reach 65 years
f age, there would be a large burden of atherosclerotic disease.
tudy limitations. Our study findings need to be inter-
reted in light of our study design since administrative
atabases have certain inherent limitations. Although the
uebec Congenital Heart Disease Database contained our
ariables of interest, additional sources of data may have
in Tab
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measures were employed to minimize misclassification of
ACHD diagnoses. A previously validated multilevel hierar-
chical algorithm was used, additional hand-checking and
auditing was performed, and nonspecific ACHD codes were
rejected. Furthermore, sensitivity analysis for each category
of ACHD and for individual ACHD lesions yielded similar
results. Patients not using the Quebec healthcare system
between 1983 and 2005 were not included in the cohort.
This may have lead to an underestimation of the prevalence
of older adults with ACHD, especially those with mild,
clinically silent disease. Inclusion of these patients may have
further inflated the impact of acquired comorbid conditions
on mortality since patients with mild ACHD would be
expected to die from ACHD-unrelated causes. Therefore,
our results provide a conservative estimate of both preva-
lence and predictors of mortality.
Prior studies addressing the burden of ACHD have been
limited by short-term follow-up and emphasis on complex
lesions being cared for in highly specialized centers (23).
The present study was population based, encompassing
Predictors of All-Cause MortalityTable 2 Predictors of All-Cause Mortality
Deaths
(n  630)
S
(n
ACHD lesion
Severe 12 (2)
Shunts 397 (63) 1,5
Valvular 221 (35) 9
Male 323 (51) 1,1
Atrial fibrillation 156 (25)
Ventricular arrhythmia 28 (4)
Sick sinus syndrome 27 (4) 1
Heart block 33 (5) 1
Endocarditis 7 (1)
Pulmonary hypertension 45 (7) 1
Erythrocytosis 18 (3)
Epilepsy 17 (3)
Diabetes 142 (23) 3
Dyslipidemia 112 (18) 7
Hypertension 305 (48) 1,2
Coronary artery disease 97 (15) 2
Myocardial infarction 70 (11) 1
Heart failure 196 (31) 4
Stroke/TIA 72 (11) 2
Chronic kidney disease 32 (5)
Chronic liver disease 17 (3)
COPD 79 (13) 1
Pneumonia 28 (4)
Thyroid disease 66 (10) 3
Cancer 118 (19) 4
Deep vein thrombosis 6 (1)
Gastrointestinal bleed 15 (2)
Depression 35 (6) 1
Dementia 7 (1)
Values are n (%).
CI  confidence interval; HR  hazard ratio; other abbreviations assimple and complex lesions, tertiary and nontertiary caresettings, and long-term follow-up. The implications of our
findings underscore the complex needs of patients with
ACHD (25), and suggests that there will be a need for
resources to care for this growing group of older adults with
ACHD: ACHD specialists to care for the small but
increasing number of severe lesions and complications,
general cardiologists to care for the burden of atherosclerotic
disease, and general practitioners and internists to care for
the multitude of acquired comorbid conditions that these
patients possess.
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